Interferon therapy in LKM-1 positive patients with chronic hepatitis C: Follow-up by a quantitative radioligand assay for CYP2D6 antibody detection

Journal of Hepatology

Volumn 28, Issue 6, 1998, Pages 965-970

  Duclos Vallée, Jean Charles ^a   Nishioka, Mikio ^b   Hosomi, Naoki ^b   Arima, Keiji ^b   Leclerq, Anne ^a   Bach, Jean François ^a   Yamamoto, Ana Maria ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Autoimmune hepatitis; CYP2D6; Hepatitis C virus; LKM 1; Radioligand assay

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; DEBRISOQUINE 4 HYDROXYLASE; ENZYME ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNE HEPATITIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY MICROSOME; LIVER MICROSOME; MALE; PRIORITY JOURNAL;

EID: 0032103905     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80344-9     Document Type: Article

References (24)

1. Alvarez F, Bernard O, Homberg JC, Kreibich G. Anti-liver-kidney microsome antibody recognizes a 50,000 molecular weight protein of the endoplasmic reticulum. J Exp Med. 161:1985;1231-1236.
2. Manns M, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 88:1991;1370-1379.
3. Gueguen M, Boniface O, Bernard O, Clerc F, Cartwright T, Alvarez F. Identification of the main epitope on human cytochrome P450IID6 recognized by anti-liver-kidney microsome antibody. J Autoimmun. 4:1991;607-615.
4. Lenzi M, Ballardini G, Fusconi M, Cassani F, Selleri L, Volta U, et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet. 335:1990;258-259.
5. Todros L, Touscoz G, D'Urso N, Durazzo M, Albano E, Poli G, et al. Hepatitis C virus-related chronic liver disease with autoantibodies to liver/kidney microsomes (LKM). J Hepatol. 13:1991;128-131.
6. Nishioka M, Morshed SA, Kono K, Himoto T, Parveen S, Arima K, et al. Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C. J Hepatol. 26:1997;992-1000.
7. Muratori L, Lenzi M, Cataleta M, Giostra F, Cassani F, Ballardini G, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis. C J Hepatol. 21:1994;199-203.
8. Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology. 22:1995;1374-1378.
9. Mayet W-J, Hess G, Gerken G, Rossol S, Voth R, Manns M, et al. Treatment of chronic type B hepatitis with recombinant α-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology. 10:1989;24-28.
10. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med. 116:1992;51-53.
11. Pateron D, Hartman DJ, Duclos-Vallée JC, Jouanolle H, Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol. 17:1993;417-419.
12. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology. 108:1995;1770-1777.
13. Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of anti-liver kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology. 104:1993;1762-1767.
14. Duclos-Vallée JC, Hajoui O, Yamamoto AM, Jacqz-Aigrain E, Alvarez F. Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies. Gastroenterology. 108:1995;470-476.
15. Yamamoto AM, Johanet C, Duclos-Vallée JC, Bustarret FA, Alvarez F, Homberg JC, et al. A new approach to cytochrome CYP2D6 antibody detection in autoimmune hepatitis type-2 (AIH-2) and chronic hepatitis C virus (HCV) infection: a sensitive and quantitative radioligand assay. Clin Exp Immunol. 108:1997;396-400.
16. Ma Y, Gregorio G, Gäken J, Muratori L, Bianchi FB, Mieli-Vergani G, et al. Establishment of a novel radioligand assay using eukaryotically expressed cytochrome P4502D6 for the measurement of liver kidney microsomal type 1 antibody in patients with autoimmune hepatitis and hepatitis C virus infection. J Hepatol. 26:1997;1396-1402.
17. Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med. 60:1990;215-222.
18. Terasaki PI, Bernocco D, Park MS, Ozturk G, Iwaki Y. Microdroplet testing for HLA-A, -B, -C and -D antigens. Am J Clin Pathol. 69:1978;103-120.
19. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 73:1992;673-679.
20. Manns MP, Krüger M. Immunogenetics of chronic liver diseases. Gastroenterology. 106:1994;1676-1697.
21. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol. 24:1996;52-59.
22. Jurado A, Cardaba B, Jara P, Cuadrado P, Hierro L, de Andrés B, et al. Autoimmune hepatitis type 2 and hepatitis C virus infection: study of HLA antigens. J Hepatol. 26:1997;983-991.
23. Pawlotsky JM, Roudot-Thoraval F, Bastie A, Darthuy F, Remire J, Metreau JM, et al. Factors affecting treatment responses to interferon-alpha in chronic hepatitis C. J Infect Dis. 174:1996;1-7.
24. Michitaka K, Durazzo M, Tillmann HL, Walker D, Philipp T, Manns MP. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology. 106:1994;1603-1610.